RESUMEN
AIM: To study the effect of the daytime anxiolytic adaptol on the efficiency and tolerability of combination treatment for atopic dermatitis (AD). SUBJECTS AND METHODS: Eighty patients with different clinical forms of AD were examined and then divided into 2 identical groups. The patients' mean age was 30.7 +/- 11.2 years; the mean disease duration was 20.2 +/- 12.8 years. Group 1 patients (n = 40) received standard treatment involving disintoxication therapy, prednisolone 30-60 mg/day, antihistamines, phototherapy (20 sessions), topical steroids and topical emollients. Group 2 patients (n = 40) took additionally adaptol as 3 tablets (1500 mg) daily. The efficiency of therapeutic measures was evaluated in 2 steps: by taking into account the changes in the scoring atopic dermatitis index (SCORAD) and the Dermatology Life Quality Index (DLQI) scores 4 weeks following the initiation of treatment and once more after 12 weeks. RESULTS: There was a tendency for the more pronounced decrease in SCORAD scores in Group 2 (using adaptol) versus Group 1 (standard treatment) to 9.8 +/- 2.57 and 10.8+ +/- 2.64, respectively. There were drops in SCORAD scores by 4.1 and 3.6 times, respectively. Twelve weeks after 12 weeks of treatment initiation was 7.1 +/- 2.13 scores in the adaptol group; on the contrary, this indicator increased slightly due to evolving recurrences and amounted to as many as 11.9 +/- 2.41 scores on the average. In Group 1, DLQI improved by 73% following 4 weeks and decreased by 1% after 12 weeks while in Group 2, it improved by 81% following 4 weeks and continued to improve up to 85% after 12 weeks. CONCLUSION: Comparison of examined dermatology indices in AD patients receiving standard treatment and treatment including adaptol gives proof to the great value and efficiency of using adaptol during an exacerbation and in the postrecurrence period.
Asunto(s)
Biureas , Dermatitis Atópica/terapia , Glucocorticoides/administración & dosificación , Antagonistas de los Receptores Histamínicos/administración & dosificación , Fototerapia/métodos , Adulto , Ansiolíticos/administración & dosificación , Ansiolíticos/efectos adversos , Biureas/administración & dosificación , Biureas/efectos adversos , Terapia Combinada , Dermatitis Atópica/diagnóstico , Dermatitis Atópica/fisiopatología , Dermatitis Atópica/psicología , Vías de Administración de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Calidad de Vida , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios , Resultado del TratamientoRESUMEN
Was examined 92 patients with congestive heart failure III-IV FC with fraction of emission left ventricle < 45% against coronary artery disease. Patients of control group received basic therapy (according to recommendations of the Ukrainian society of cardiology), the 1 group--in addition received a preparation of Vazonat within 15 days intravenously in a dose of 1000 mg a day further are out-patient within 1 month on 250 mg 3 times per os; the 2 group--under the same scheme a preparation of Vazonat and a day tranquilizer of Adapto in a dose of 500 mg twice a day throughout all term of supervision. It is established that addition of Vazonat to basic treatment leads to additional effect concerning improvement of indicators cardio-hemodynamic, to improvement congestive functions. Joint appointment of preparations of Vazonat and Adaptol against basic treatment leads to more expressed improvement congestive functions, to progressive reduction of degree of trouble, depression.
Asunto(s)
Ansiolíticos/uso terapéutico , Biureas/uso terapéutico , Fármacos Cardiovasculares/uso terapéutico , Insuficiencia Cardíaca/tratamiento farmacológico , Metilhidrazinas/uso terapéutico , Trastornos Psicofisiológicos/tratamiento farmacológico , Anciano , Ansiolíticos/administración & dosificación , Ansiolíticos/efectos adversos , Biureas/administración & dosificación , Biureas/efectos adversos , Fármacos Cardiovasculares/administración & dosificación , Fármacos Cardiovasculares/efectos adversos , Cognición/efectos de los fármacos , Quimioterapia Combinada , Ecocardiografía , Prueba de Esfuerzo , Insuficiencia Cardíaca/patología , Insuficiencia Cardíaca/fisiopatología , Insuficiencia Cardíaca/psicología , Hemodinámica/efectos de los fármacos , Humanos , Metilhidrazinas/administración & dosificación , Metilhidrazinas/efectos adversos , Persona de Mediana Edad , Contracción Miocárdica/efectos de los fármacos , Miocardio/patología , Pruebas Neuropsicológicas , Trastornos Psicofisiológicos/fisiopatología , Trastornos Psicofisiológicos/psicología , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
AIM: To evaluate the efficacy and safety of adaptol in a dose of 1500-2000 mg/day in combination therapy for anxiety disorders (AD) in the early post-myocardial infarction period. SUBJECTS AND METHODS: The trial included 94 patients with AD who were divided into a study group of 60 patients and a control group of 34 patients. In addition to basic therapy, the study group took adaptol in a dose of 1500-200 mg/day for 30 +/- 2 days; the control group received basic therapy only. RESULTS: The drug given in a dose of 1500-2000 mg/day in the patients with AD in the early post-myocardial infarction period was found to have high anxiolytic, autonomically normalizing, stress-protective activities and a positive effect on heart rate variability just one month after treatment. The highest efficacy of Adaptol was observed in patients with baseline hypersympathicotonic and normal autonomic responsiveness. CONCLUSION: Adaptol proved to be more effective in patients with baseline hypersympathicotonic and normal autonomic responsiveness, which permits the drug to be differentially used in relation to the baseline type of autonomic responsiveness.
Asunto(s)
Ansiolíticos/farmacología , Trastornos de Ansiedad/tratamiento farmacológico , Biureas/farmacología , Infarto del Miocardio/tratamiento farmacológico , Ansiolíticos/administración & dosificación , Ansiolíticos/efectos adversos , Biureas/administración & dosificación , Biureas/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de Tiempo , Resultado del TratamientoRESUMEN
The authors present the results of examination of 34 patients, aged from 18 to 30 years, with attention deficit hyperactivity disorder (ADHD) (ICD-10 item F90.0). The study has shown that inattentive type of ADHD is noted in 50%, combined type in 38.3% and hyperactivity/impulsivity type in 11.7% of patients. Adult patients with ADHD also have a high level of anxiety and asthenic disorders. This study evaluated the efficacy and safety of adaptol in dosage 1500 mg daily during 8 weeks in the treatment of this group of patients. The high efficacy (improvement in 64,7% of cases) and safety of adaptol confirmed by the data of clinical, psychological and neurophysiological studies.
Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad/psicología , Atención , Biureas/uso terapéutico , Adolescente , Adulto , Ansiolíticos/administración & dosificación , Ansiolíticos/uso terapéutico , Trastorno por Déficit de Atención con Hiperactividad/tratamiento farmacológico , Biureas/administración & dosificación , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Humanos , Conducta Impulsiva/tratamiento farmacológico , Psicofisiología , Síndrome , Resultado del Tratamiento , Adulto JovenRESUMEN
AIM: To evaluate the effect of the anxiolytic adaptol on blood pressure (BP) level in its concurrent use with a fixed dose angiotensin-converting enzyme (ACE) inhibitor/diuretic combination on quality of life and on the correction of psychoautonomic disorders. SUBJECTS AND METHODS: The trial included women aged 40-60 years with the verified diagnosis of Stage 2B arterial hypertension (AH), risk 2, and a disease history of at least 5 years. A study group received a fixed dose ACE inhibitor/diuretic combination once daily and adaptol 500 mg twice daily for 2 months. A comparison group had only the fixed dose ACE inhibitor/diuretic combination once daily without adaptol. RESULTS: By the end of one-month therapy, a more pronounced statistically significant BP reduction was achieved in the study group receiving the ACE inhibitor/diuretic combination and adaptol than in the comparison group. The quality of life was improved in 6 of the 8 items in the study group and in 3 items in the comparison group. The total scores of psychoautonomic disorders decreased from 48.7 to 25.8 in the study group and from 47.8 to 38 in the comparison one. CONCLUSION: It is expedient to combine antihypertensive therapy and anxiolytics in female hypertensive patients with autonomic dystonic disorders.
Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina , Biureas , Diuréticos , Hipertensión/tratamiento farmacológico , Adulto , Inhibidores de la Enzima Convertidora de Angiotensina/administración & dosificación , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Ansiolíticos/administración & dosificación , Ansiolíticos/uso terapéutico , Biureas/administración & dosificación , Biureas/farmacología , Diuréticos/administración & dosificación , Diuréticos/farmacología , Quimioterapia Combinada , Femenino , Humanos , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
There is a presents a clinical case of idiopathic ventricular arrhythmia developing in a 27-year-old young woman with anxiety neurosis successfully treated with the anxiolytic Adaptol used in daily dosage 1500 mg during a month.
Asunto(s)
Ansiolíticos/administración & dosificación , Trastornos de Ansiedad/tratamiento farmacológico , Arritmias Cardíacas/tratamiento farmacológico , Biureas/administración & dosificación , Adulto , Trastornos de Ansiedad/complicaciones , Trastornos de Ansiedad/fisiopatología , Arritmias Cardíacas/etiología , Electrocardiografía Ambulatoria , Femenino , Ventrículos Cardíacos/efectos de los fármacos , Ventrículos Cardíacos/fisiopatología , Humanos , Estrés Psicológico/complicaciones , Resultado del TratamientoRESUMEN
AIM: To comparatively analyze the efficiency of combination treatment in patients with chronic prostatitis. SUBJECTS AND METHODS: Psychometric and psychological methods, such as the Hamilton depression rating scale and the Hamilton anxiety rating scale, determination of the types of an attitude toward illness, and the personality rating questionnaire, were used to examine 80 men with chronic bacterial prostatitis (CBP) who were allocated to 2 groups. A study group received levofloxacin in combination with adaptol for 10 days; a control group had antibacterial therapy only. RESULTS: The patients receiving adaptol were ascertained to have a more evident normalization of mental disorders, as shown by the scales, as lower scores: 4.9 +/- 0.6 for irritability, 5.7 +/- 0.6 for reactive aggression, 5.1 +/- 0.7 for shyness, and as a higher score (up to 5.2 +/- 1.3) for sociability (p < 0.05). There was a pronounced reduction in diurnal mood variations, which is indicative of relief of anxiety and depressive disorders. CONCLUSION: The use of adaptol in a dose of 500 mg thrice daily for 10 days as part of the combination treatment of patients with an exacerbation of CBP permits correction of the mental status and improves the quality of life of patients in a shorter period of treatment.
Asunto(s)
Ansiolíticos/administración & dosificación , Antiinfecciosos Urinarios/administración & dosificación , Biureas/administración & dosificación , Levofloxacino , Ofloxacino/administración & dosificación , Prostatitis/tratamiento farmacológico , Prostatitis/psicología , Adulto , Quimioterapia Combinada , Humanos , Masculino , Persona de Mediana Edad , Prostatitis/microbiología , Escalas de Valoración Psiquiátrica , Resultado del Tratamiento , Adulto JovenRESUMEN
We have studied the efficacy of adaptol in the treatment of 45 patients with somatoform dysfunction of the autonomic nervous system and 30 patients with closed head injury. The condition of patients during the treatment was evaluated with clinical and neuropsychological scales. The serum level of BDNF before and after the treatment has been studied as well. Adaptol has been shown to enhance the production of BDNF, reduce significantly the intensity of anxiety, autonomic disorders and improve intellectual processes. The dose-dependent effect of the drug has been demonstrated. In conclusion, adaptol can be recommended for treatment of diseases that demand stimulation of neuroplasticity in the CNS.
Asunto(s)
Ansiolíticos/uso terapéutico , Trastornos de Ansiedad/tratamiento farmacológico , Enfermedades del Sistema Nervioso Autónomo/tratamiento farmacológico , Biureas/uso terapéutico , Factor Neurotrófico Derivado del Encéfalo/sangre , Trastornos del Conocimiento/tratamiento farmacológico , Trastornos Fóbicos/tratamiento farmacológico , Adolescente , Adulto , Ansiolíticos/administración & dosificación , Trastornos de Ansiedad/sangre , Enfermedades del Sistema Nervioso Autónomo/sangre , Biureas/administración & dosificación , Trastornos del Conocimiento/sangre , Relación Dosis-Respuesta a Droga , Humanos , Persona de Mediana Edad , Trastornos Fóbicos/sangre , Pronóstico , Resultado del Tratamiento , Adulto JovenRESUMEN
Psychosomatic presentations of generalized anxiety disorder (GAD) and an estimation of efficacy of adaptol in the treatment of patients with this pathology have been studied. The results of clinical examination of 67 patients with GAD , aged from 18 to 45 years, are presented. Adaptol was administered in dose 1500 mg daily during 60 days in 35 patients. The improvement was noted in 68,6% of cases. The high clinical efficacy of adaptol and the absence of side-effects are reported.
Asunto(s)
Ansiolíticos/administración & dosificación , Trastornos de Ansiedad/diagnóstico , Trastornos de Ansiedad/tratamiento farmacológico , Biureas/administración & dosificación , Trastornos Psicofisiológicos/diagnóstico , Trastornos Psicofisiológicos/tratamiento farmacológico , Adolescente , Adulto , Ansiolíticos/efectos adversos , Biureas/efectos adversos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Adulto JovenRESUMEN
We examined 162 patients, aged from 10 to 15 years, with tic hyperkineses. Transient and chronic tic disorders were observed in 82 and 80 patients, respectively. The relationship of clinical features, frequency, psychological and encephalographic characteristics of the patients with age-at-onset was studied. The effect of adaptol on the course of chronic tic disorders was evaluated. In addition to our results reported previously for transient tic disorders, we demonstrated the efficacy of adaptol administered in dose 1000 mg per day during 60 days in patients with chronic tic disorders.
Asunto(s)
Analgésicos/uso terapéutico , Biureas/uso terapéutico , Trastornos de Tic/diagnóstico , Trastornos de Tic/tratamiento farmacológico , Adolescente , Analgésicos/administración & dosificación , Biureas/administración & dosificación , Niño , Enfermedad Crónica , Femenino , Humanos , Masculino , Resultado del TratamientoRESUMEN
AIM: To assess whether arrhythmias may be corrected with the anxiolytic Adaptol in subjects with anxiety disorders. SUBJECTS AND METHODS: On the basis of the data of psychological and mental testing (Stroop test) and the results of Holter monitoring, the authors selected among 59 patients with non-coronarogenic ventricular arrhythmias (VA) and an inadequate response to antiarrhythmic therapy 21 patients with manifest anxiety disorders, in whom a psychogenic factor had played a significant role in the genesis of VA, which served as an indication for Adaptol use. Reexaminations were made 30 days after initiation of therapy with Adaptol 500 mg t.i.d. RESULTS: Adaptol used to treat VA in patients with high anxiety, unlike the controls, exerted a significant antiarrhythmic effect: the average daily and average hourly number of ventricular ectopic complexes significantly decreased while there were no changes in the control group (untreated with Adaptol). In 95% of the patients, the positive Stroop mental test became negative, i.e. it failed to provoke arrhythmia (p < or = 0.01), made test performance easy, and diminished a blood pressure response to the test. The number of patients with moderate and high situational anxiety decreased by 3 times (p < or = 0.01); the general condition improved in the majority of patients. CONCLUSION: The psychogenic factor plays a significant and sometimes determining role in the genesis of non-coronarogenic VA. When used alone and in combination with antiarrthythmics, Adaptol proved to be effective in treating non-coronarogenic VA in patients with higher anxiety.
Asunto(s)
Ansiedad/tratamiento farmacológico , Biureas , Pruebas Psicológicas , Complejos Prematuros Ventriculares , Adulto , Ansiolíticos/administración & dosificación , Ansiolíticos/efectos adversos , Antiarrítmicos , Ansiedad/complicaciones , Ansiedad/fisiopatología , Biureas/administración & dosificación , Biureas/efectos adversos , Monitoreo de Drogas/métodos , Electrocardiografía Ambulatoria , Prueba de Esfuerzo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Complejos Prematuros Ventriculares/diagnóstico , Complejos Prematuros Ventriculares/tratamiento farmacológico , Complejos Prematuros Ventriculares/etiología , Complejos Prematuros Ventriculares/psicologíaRESUMEN
The authors present the results of clinical, physiological and psychological examination of 31 patients with neurocirculatory asthenia with arterial hypertension syndrome. There was an increase in the levels of state and trait anxiety correlated with a number of physiological traits that confirmed a leading role of psycho-emotional sphere in the formation of hypertensive reactions. An evaluation of the efficacy of the drug Adaptol used in daily dosage 1500 mg during 8 weeks in the treatment of these patients revealed its high efficacy (the improvement was seen in 74% of cases) confirmed by the data of clinical and psychological studies.
Asunto(s)
Ansiolíticos/uso terapéutico , Biureas/uso terapéutico , Hipertensión/tratamiento farmacológico , Astenia Neurocirculatoria/tratamiento farmacológico , Adulto , Ansiolíticos/administración & dosificación , Biureas/administración & dosificación , Femenino , Humanos , Hipertensión/fisiopatología , Hipertensión/psicología , Masculino , Astenia Neurocirculatoria/fisiopatología , Astenia Neurocirculatoria/psicología , Síndrome , Resultado del TratamientoRESUMEN
Sixty-eight patients, aged from 40 to 70 years, with discirculatory encephalopathy, I and II stages, have been examined. Thirty-five patients of the main group received non-benzodiazepine tranquilizer adaptol in dose 500 mg 2 times daily in addition to regular vasoactive treatment and 33 patients of the control group received only regular treatment. The following characteristics were assessed at baseline and after 1 month of treatment: complaints and neurological status, anxiety level (the Spielberger-Khanin scale), quality of life (SF-36) and parameters of P300 cognitive evoked potentials. To the end of treatment, there were the significant decrease of state and trait anxiety, improvement of quality of life, decrease of P300 latencies and increase of P300 amplitudes. No significant side-effects were seen, only 2 (5.7%) patients had transitory dyspepsia. In conclusion, adaptol in dose 1000 mg daily is effective and safe for the complex treatment of discirculatory encephalopathy of I and II stages.
Asunto(s)
Ansiolíticos/uso terapéutico , Biureas/uso terapéutico , Trastornos Cerebrovasculares/tratamiento farmacológico , Adulto , Anciano , Ansiolíticos/administración & dosificación , Ansiolíticos/efectos adversos , Biureas/administración & dosificación , Biureas/efectos adversos , Trastornos Cerebrovasculares/fisiopatología , Quimioterapia Combinada , Dispepsia/inducido químicamente , Dispepsia/diagnóstico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
The anti-inflammatory activity of amitriptyline, diazepam and a new, Russian tranquilizer mebicar was studied in a wide range of therapeutic doses on carrageenan-induced paw edema in rats. Mebicar at low doses showed greater and longer (up to 24 h) lasting anti-inflammatory activity as compared to that of amitriptyline and diazepam.
Asunto(s)
Amitriptilina/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Biureas/uso terapéutico , Diazepam/uso terapéutico , Edema/tratamiento farmacológico , Enfermedades del Pie/tratamiento farmacológico , Amitriptilina/administración & dosificación , Amitriptilina/farmacología , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacología , Biureas/administración & dosificación , Biureas/farmacología , Carragenina/farmacología , Diazepam/administración & dosificación , Diazepam/farmacología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Edema/inducido químicamente , Femenino , Enfermedades del Pie/inducido químicamente , Masculino , RatasRESUMEN
The study aimed at therapeutic effect of adaptol on burn-out syndrome. Authors examined 32 patients aged from 25 to 45 years. Adaptol was prescribed in day dose 1500 mg during 60 days. Clinical, psychological and electroencephalographic study (EEG) was conducted before and after the treatment course. The data of adaptol positive influence on the basic clinical symptoms (reduction of asthenic and anxiety scores) is obtained. The analysis of EEG results allows to draw conclusions on normalisation of brain functional activity after therapy.
Asunto(s)
Trastornos de Ansiedad/tratamiento farmacológico , Biureas/uso terapéutico , Agotamiento Profesional/tratamiento farmacológico , Adulto , Trastornos de Ansiedad/fisiopatología , Trastornos de Ansiedad/psicología , Ritmo beta , Biureas/administración & dosificación , Biureas/efectos adversos , Encéfalo/fisiopatología , Agotamiento Profesional/fisiopatología , Agotamiento Profesional/psicología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Resultado del TratamientoRESUMEN
Developmental toxicity of isobutylidenediurea (IBDU) was determined by oral administration to Wistar rats. The substance was administered as an aqueous suspension to 22-24 pregnant rats per group by gavage in daily doses of 100, 400 and 1000 mg/kg body weight from day 6 post-coitum (p.c.) to day 15 p.c. The control group received the vehicle only (0.5% aqueous carboxymethyl cellulose solution). There were no substance-related effects in the dams concerning food consumption, body weight, body weight gain, uterine weights and clinical or autopsy observations even at the highest dose of 1000 mg/kg body weight/day. The reproduction data revealed no biologically relevant differences between the control and treated groups. The incidence and type of the foetal external, soft tissue and skeletal findings, which were classified as malformations, variations and/or retardations observed in the treated foetuses were similar to the concurrent and/or historical control data. Thus, under the conditions of this study, no signs of maternal toxicity or embryo/foetotoxicity were induced by IBDU and the no-observable-adverse-effect level on the maternal and developing organism was 1000 mg/kg body weight/day.
Asunto(s)
Biureas/toxicidad , Desarrollo Embrionario y Fetal/efectos de los fármacos , Fertilizantes/toxicidad , Anomalías Inducidas por Medicamentos , Administración Oral , Animales , Biureas/administración & dosificación , Femenino , Masculino , Nivel sin Efectos Adversos Observados , Embarazo , Ratas , Ratas Wistar/embriología , Aumento de Peso/efectos de los fármacosRESUMEN
Isobutylidene diurea (IBDU) was tested against urea with regard to the ammonia release in the rumen, the amount and composition of the nitrogen fraction reaching the intestine, the nitrogen and energy balances and the performance of lactating cows. Maize silage was the basal feed in all experiments. The ammonia concentration in the rumen liquor was measured in two dry cows fitted with a permanent rumen cannula. The ammonia release was clearly restrained when IBDU was substituted for urea, and the peak values were of the same order as those found with soybean meal. Two dry cows fitted with a re-entrant cannula at 10 cm from the pylorus were fed with maize silage supplemented with increasing amounts of either urea or IBDU. The duodenal flow levelled off with urea, but it continued to rise with IBDU even when high amounts were added to the silage. However, a large fraction of this increase was in the form of ammonia, corresponding to 60% of the dietary nitrogen supplied by IBDU. The amount of non-ammonia nitrogen was also higher with IBDU. The nitrogen balance of lactating cows was not noticeably affected when IBDU instead of urea was added to the maize silage. In the same manner, the digestibility of the rations and their metabolizable energy supply were not significantly modified, and the milk productions were quite similar with the two N compounds, apart from the tendency to lower milk fat and milk protein productions.
Asunto(s)
Biureas/administración & dosificación , Bovinos/metabolismo , Urea/metabolismo , Amoníaco/metabolismo , Alimentación Animal/análisis , Animales , Biureas/metabolismo , Metabolismo Energético/efectos de los fármacos , Femenino , Contenido Digestivo/análisis , Leche/efectos de los fármacos , Nitrógeno/metabolismo , Valor Nutritivo , Embarazo , Rumen/metabolismo , SolubilidadRESUMEN
The authors review the principles of calculating the optimal dosage regimens of mebicar used in the treatment of borderline psychopathological abnormalities in alcoholics. Mebicar administered to patients according to the calculated dosage regimens ensures the positive clinical effect. This is supported by the clinicopsychopathological and electrophysiological data.